Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 3/20 | 0.31 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7208634 | 0.85 | LMNA (0.38) | P2RY6LMNASMN1; SMN2 | |
| SCHEMBL7209718 | 0.80 | TDP1 (0.36) | TDP1P2RY6LMNATHRBSMN1; SMN2 | |
| SCHEMBL20879426 | 0.77 | TDP1 (0.36) | TDP1DUTP2RY6LMNATHRB | |
| SCHEMBL25573323 | 0.77 | TDP1 (0.36) | TDP1DUTP2RY6LMNATHRB | |
| SCHEMBL9548689 | 0.76 | DUT (0.36) | TDP1DUTP2RY6 | |
| SCHEMBL9548693 | 0.76 | DUT (0.36) | TDP1DUTP2RY6 | |
| SCHEMBL9548669 | 0.76 | DUT (0.38) | TDP1DUTP2RY6 | |
| SCHEMBL9548678 | 0.76 | DUT (0.38) | TDP1DUTP2RY6 | |
| SCHEMBL23054812 | 0.72 | TDP1 (0.38) | TDP1DUTP2RY6 | |
| SCHEMBL22609164 | 0.72 | TDP1 (0.38) | TDP1DUTP2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177201-B1 | 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES | YAMASA CORP (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-6403568-B1 | FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) | YAMASA CORPORATION (JP) | 2002-06-11 | — | — | US | disclosed |
| US-20020022722-A1 | 4'-C-ethynyl pyrimidine nucleoside compounds | OHRUI HIROSHI (JP) | 2002-02-21 | — | — | US | disclosed |
| US-6333315-B1 | FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022722-A1 | 4'-C-ethynyl pyrimidine nucleoside compounds | PNP, TYMP, NUDT1 | TDP1 315/4885DUT 9/4885P2RY6 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.